Cowen analyst Joesph Thome initiated coverage of Xenon Pharmaceuticals with an Outperform rating, telling investors that he is "optimistic" about the successful development of lead asset XEN1101, a potassium channel opener for the treatment of epilepsy and depression, given what he calls "the compelling data generated to date." He sees XEN1101’s efficacy and safety profile as "compelling" and models a launch in 2026, with peak U.S. sales of $1.3B in 2039, Thome tells investors.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on XENE:
- Xenon Pharmaceuticals initiated with an Outperform at Cowen
- Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
- Xenon Pharmaceuticals provides updates on neurology programs at AES 2022
- Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
- Xenon Pharmaceuticals initiated with an Overweight at Wells Fargo
